Compare SPRO & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | CSBR |
|---|---|---|
| Founded | 2013 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 81.0M |
| IPO Year | 2017 | 2015 |
| Metric | SPRO | CSBR |
|---|---|---|
| Price | $1.21 | $5.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 607.0K | 8.2K |
| Earning Date | 05-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | $2,900,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | $300.00 | $11.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $1.08 | $4.83 |
| 52 Week High | $3.08 | $8.74 |
| Indicator | SPRO | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 34.07 | 41.91 |
| Support Level | $1.18 | $4.83 |
| Resistance Level | $1.29 | $6.31 |
| Average True Range (ATR) | 0.05 | 0.25 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 16.00 | 33.98 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.